SAN MATEO, Calif., March 18 /PRNewswire-FirstCall/ -- NeurogesX, Inc. (Nasdaq: NGSX), a biopharmaceutical company focused on developing and commercializing novel pain management therapies, today announced it will report results for its fourth quarter and year-end 2007 on Wednesday, March 26, 2008, after the market closes.
A conference call to review the results will begin at 5:00 p.m. ET (2:00 p.m. PT) on March 26, 2008 and will be hosted by Anthony DiTonno, President and Chief Executive Officer, and Stephen Ghiglieri, Chief Financial Officer.
To participate in the conference call, please dial 1-877-407-0789 (USA) or 1-201-689-8562 (International). In addition, a dial-up replay of the conference call will be available beginning March 26, 2008 at 8:00 p.m. ET (5:00 p.m. PT) and ending on April 5, 2008. The replay telephone number is 1- 877-660-6853 (USA) or 1-201-612-7415 (International), Account Number: 3055, Conference ID Number: 275941.
A live web cast of the call will also be available from the Investor Relations section on the corporate web site at http://www.neurogesx.com. A web cast replay can be accessed on the corporate web site beginning March 26, 2008 at approximately 6:00 p.m. ET. The replay will remain available until April 26, 2008.
About NeurogesX, Inc.
NeurogesX (Nasdaq: NGSX) is a biopharmaceutical company focused on developing and commercializing novel pain management therapies. Its initial focus is on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP) and painful diabetic neuropathy (PDN). NeurogesX' late stage product portfolio is led by its product candidate NGX-4010, a dermal patch designed to manage pain associated with peripheral neuropathic pain conditions, that the company believes offers significant advantages over other pain therapies.
Safe Harbor Statement
This press release contains forward-looking statements for purposes of
the Private Securities Litigation Reform Act of 1995 (the "Act"). NeurogesX
disclaims any intent or obligation to update these forward-looking
statements, and claims the protection of the Safe Harbor for
forward-looking statements contained in the Act. Examples of such
statements include, but are not limited to, statements concerning future
presentations by NeurogesX and the expected benefits of NeurogesX'
potential products, including its lead product candidate NGX-4010. Such
statements are based on management's current expectations, but actual
results may differ materially due to various risks and uncertainties,
including, but not limited to, past results of clinical trials may not be
indicative of future clinical trials results; NeurogesX' product candidate
may have unexpected adverse side effects or inadequate therapeutic
efficacy; positive results in clinical trials may not be sufficient to
obtain FDA or European regulatory approval; physician or patient reluctance
to use NGX-4010, if approved, or the inability of physicians to obtain
sufficient reimbursement for such procedures; potential alternative
therapies; maintaining adequate patent or trade secret protection without
violating the intellectual property rights of others; and other
difficulties or delays in clinical development, obtaining regulatory
approval, market acceptance and commercialization of NGX-4010 and the
advantages of NGX-4010 over other pain therapies. For further information
regarding these and other risks related to NeurogesX' business, investors
should consult NeurogesX' filings with the Securities and Exchange
NeurogesX, Inc. The Ruth Group
Stephen Ghiglieri Investors / Media
(650) 358-3300 Stephanie Carrington / Jason Rando
(646) 536-7017 / 7025
|SOURCE NeurogesX, Inc.|
Copyright©2008 PR Newswire.
All rights reserved